Biventricular pacing cardiac contractility modulation improves cardiac contractile function via upregulating SERCA2 and miR-133 in a rabbit model of congestive heart failure

Cellular Physiology and Biochemistry

Volumn 33, Issue 5, 2014, Pages 1389-1399

  Ning, Bin ^a   Qi, Xiaoyong ^b   Li, Yingxiao ^b   Liu, Huiliang ^b   Zhang, Feifei ^a   Qin, Chen ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

Author keywords

Absolute refractory period; Cardiac contractile function; Cardiac contractility modulation (CCM); Cardiac resynchronization therapy (CRT); Congestive heart failure; Electric pacing; miR 133; NCX1; Phospholamban; SERCA2a

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; MICRORNA; MICRORNA 133; PROTEIN; SERCA2 PROTEIN; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE (CALCIUM); SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ROOT; ARTICLE; BIVENTRICULAR ELECTRICAL PACING; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR PARAMETERS; COMPARATIVE EFFECTIVENESS; CONCENTRATION (PARAMETERS); CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CONVENTIONAL SINGLEVENTRICULAR PACING; ELECTROCARDIOGRAM; ELECTROSTIMULATION; FEMALE; FRACTIONAL SHORTENING FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE END DIASTOLIC DIAMETER; HEART LEFT VENTRICLE END SYSTOLIC DIAMETER; HEART LEFT VENTRICLE WALL; HEART MUSCLE CONTRACTILITY; HEART RIGHT VENTRICLE; HEART WEIGHT; MALE; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; RABBIT MODEL; REFRACTORY PERIOD; UPREGULATION; CARDIAC CONTRACTILITY MODULATION; CONVENTIONAL SINGLE VENTRICULAR PACING; ENDOPLASMIC RETICULUM; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; SARCOPLASMIC RETICULUM; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GENETICS; HEART CONTRACTION; HEART FAILURE; HEART PACING; METABOLISM; RABBIT;

ORYCTOLAGUS CUNICULUS;

ANIMALS; CARDIAC PACING, ARTIFICIAL; DISEASE MODELS, ANIMAL; FEMALE; HEART FAILURE; MALE; MICRORNAS; MYOCARDIAL CONTRACTION; RABBITS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; UP-REGULATION;

EID: 84900876875     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000358705     Document Type: Article

References (42)

1. Ho KL, Pinsky JL, Kannel WB, Levy D: The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993;22:6A-13A. (Pubitemid 23285789)
2. Pappone C, Rosanio S, Burkhoff D, Mika Y, Vicedomini G, Augello G, Shemer I, Prutchi D, Haddad W, Aviv R, Snir Y, Kronzon I, Alfieri O, Ben-Haim SA: Cardiac contractility modulation by elect ric currents applied during the refractory period in patients with heartfailure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2002;90:1307-1313. (Pubitemid 35449475)
3. Pappone C, Vicedomini G, Salvati A, Meloni C, Haddad W, Aviv R, Mika Y, Darvish N, Kimchy Y, Shemer I, Snir Y, Pruchi D, Ben-Haim SA, Kronzon I: Electrical modulation of cardiac contractility: Clinical aspects in congestive heart failure. H eart Fail Rev 2001;6:55-60. (Pubitemid 32328168)
4. Lyon AR, Samara MA, Feldman DS: Cardiac contractility modulation therapy in advanced systolic heart failure. Nat Rev Cardiol 2013;10:584-598.
5. Borggrefe M, Burkhoff D: Clinical effects of cardiac contractility modulation (CCM) as a treatment for chronic heart failure. Eur J Heart Fail 2012;14:703-712.
6. Cobb V, Thomas M: Cardiac resyn chronization therapy. Br J Hosp Med (Lond) 2013;74:265-270.
7. Zhang Q, Chan YS, Liang YJ, Fang F, Lam YY, Chan CP, Lee AP, Chan KC, Wu EB, Yu CM: Comparison of left ventricular re verse remodeling induced by cardiac contractility modulation and cardiac resynchronization therapy in heart failure patients with different QRS durations. Int J Cardiol 2013;167:889-893.
8. Bristow MR, Saxon LA, B oehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM: Cardiac resynchronization therapy with or without an Implantable defibrillator in advanced chronic heart fa ilure. N Engl J Med 2004;350:2140-2150.
9. Park WJ, Oh JG: SERCA2a: A prime target for modulation of cardiac contractility during heart failure. BMB Rep 2013;46:237-243.
10. Krania s EG, Hajjar RJ: Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 2012;110:1646-1660.
11. Papolos A, Frishman WH: Sarcoendoplasmic reticulum calcium transport ATPase 2a: A potential gene therapy target in heart failure. Cardiol Rev 2013;21:151-154.
12. Gwathmey JK, Yerevanian AI, Hajjar RJ: Cardiac gene therapy with SERCA2a: From bench to bedside. J Mol Cell Cardiol 2011;50:803-812.
13. Koss KL, Kranias EG: Phospholamban: A prominent regulator of myocardial contractility. Circ Res 1996;79:1059-1063. (Pubitemid 26404138)
14. Arkin IT Adams PD Brunger AT Smi th SO Engelman DM Structural perspectives of phospholamban, a helical transmembrane pentamer Ann Rev Biophys Biomol Struct 1997 26157-179. (Pubitemid 27255371)
15. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J Jr, Kranias EG, Giles WR, Chien KR: Chronic phospholamban- sarcoplasmic reticulum calcium ATPase interaction is th e critical calcium cycling defect in dilated cardiomyopathy. Cell 1999;99:313-322. (Pubitemid 29519910)
16. Menick DR, Li MS, Chernysh O, Renaud L, Kimbrough D, Kasiganesan H, Mani SK: Transcriptional pathways and p otential therapeutic targets in the regulation of Ncx1 expression in cardiac hypertrophy and failure. Adv Exp Med Biol 2013;961:125-135.
17. Roos KP, Jordan MC, Fishbein MC, Ritter MR, Friedlander M, Ch ang HC, Rahgozar P, Han T, Garcia AJ, Maclellan WR, Ross RS, Philipson KD: Hypertrophy and heart failure in mice overexpressing the cardiac sodium-calcium exchanger. J Card Fail 2007;13:318-329. (Pubitemid 46756340)
18. Menick DR, Renaud L, Buchholz A, Muller JG, Zhou H, Kappler CS, Kubalak SW, Conway SJ, Xu L: Regulation of Ncx1 gene expression in the normal and hypertrophic heart. Ann N Y Acad Sci 2007;1099: 195-203. (Pubitemid 47092621)
19. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Hpydal M, Autore C, Russo MA, Dorn GW, Elli ngsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G: MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007;13:613-618. (Pubitemid 46828487)
20. Danowski N, Manthey I, Jakob HG, Siffert W , Peters J, Frey UH: Decreased expression of miR-133a but not of miR-1 is associated with signs of heart failure in patients undergoing coronary bypass surgery. Cardiology 2013;125:125-130.
21. Schipper ME, Van Kuik J, De Jonge N, Dullens HF, De Weger RA: Changes in regulatory microRNA expression in myocardium of heart failure patients on left ventricular assist device support. J Heart Lung Transplant 2008;27:1282-1285 .
22. Sucharov C, Bristow MR, Port JD: MiRNA expression in the failing human heart: Functional correlates. J Mol Cell Cardiol 2008;45:185-192.
23. Mancini D, Burkhoff D: Mechanical device-based methods of managing and treating heart failure. Circulation J 2005;112:438-448. (Pubitemid 41022087)
24. Imai M, Rastogi S, Gupta RC, Mishra S, Sharov VG, Stanley WC, Mika Y, Rousso B, Burkhoff D, Ben-Hai m S, Sabbah HN: Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol 2007;49:2120-2128. (Pubitemid 46771049)
25. Zhang H, Cui C, Hu D: Effects of electric stimulations applied during absolute refractory period on cardiac function of rabbits with heart failure. J Huazhong Univ Sci Technol 2010;30:155-158.
26. Callans DJ, Fu chs S, Mika Y, Shemer I, Aviv R, Haddad W, Darvish N, Ben-Haim SA, Kornowski R: Global improvement in left ventricular performances observed with cardiac contractility modulation is the result of changes in regional contra ctility . Heart Fail Rev 2001;6:35-44. (Pubitemid 32328166)
27. Villar AV, Merino D, Wenner M, Llano M, Cobo M, Montalvo C, Garcia R, Martin-Duran R, Hurle JM, Hurle MA, Nistal JF: Myocardial gene exp ression of microRNA-133a and myosin heavy and light chains, in conjunction with clinical parameters, predict regression of left ventricular hypertrophy after valve replacement in patients with aortic stenosis. Heart 2011;97:1132-1137 .
28. Li Q, Lin X, Yang X, Chang J: NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression. Am J Physiol Heart Circ Physiol 2010;298:H1340-H1347.
29. Burkhoff D, Shemer I, Felzen B, Shimizu J, Mika Y, Dickstein M, Prutchi D, Darvish N, Ben-Haim SA: Electric currents applied during the refractory can modulate cardiac contractility in vitro and in vivo. H eart Fail Rev 2001;6:27-34. (Pubitemid 32328165)
30. Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H, Gasparini M, Linde C, Morgado FB, Oto A, Sutton R, Trusz-Gluza M; European Society of Cardiology; European Heart Rhythm Association: Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration w ith the European Heart Rhythm Association. Eur Heart J 2007;28:2256-2295.
31. Sweeney MO, Van Bommel RJ, Schalij MJ, Borleffs CJ, Hellkamp AS, Bax JJ: Analysis of ventricular activation using surface elec trocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynehronization therapy. Circulation 2010;121:626-634.
32. Butter C, Rastogi S, Minden HH, Meyhofer J, Burkhoff D, Sabbah HN: Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure. J Am Coll Cardiol 2008;51:1784-1789. (Pubitemid 351608495)
33. Cerra MC, Imbrogno S: Phospholamba n and cardiac function: A comparative perspective in vertebrates. Acta Physiol (Oxf) 2012;205:9-25.
34. Movsesian MA: CAMP-mediated signal transduction and sarcoplasmic reticulum function in heart failure. Ann N Y Acad Sci 1998;853:231-239. (Pubitemid 28515045)
35. Marks AR Calcium cycling proteins and heart failure: Mechanisms and therapeutics. J Clin Invest 2013 123 46-52.
36. Zhang L, Wu Y, Li Y, Xu C, Li X, Zhu D, Zhang Y, Xing S, Wang H, Zhang Z, Shan H: Tanshinone IIA improves miR-133 expression through MAPK ERK1/2 pathway in hypoxic cardiac myocytes. Cell Physiol Biochem 2012;30:843-852.
37. Salloum FN, Yin C, Kukreja RC: Role of microRNAs in cardiac preconditioning. J Cardiovasc Pharmacol 2010;56:581-588.
38. Ye Y, Perez-Polo JR, Qian J, Birnbaum Y: The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol Genomics 2011;43:534-542.
39. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, Van Der Made I, Herias V, Van Leeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S,Pinto YM, Creemers EE: MiR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009; 104:170-178.
40. Shan H, Zhang Y, Lu Y, Zhang Y, Pan Z, Cai B, Wang N, Li X, Feng T, Hong Y, Yang B: Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res 2009;83:465-472.
41. Horie T, Ono K, Nishi H, Iwanaga Y, Nagao K, Kinoshita M, Kuwabara Y, Takanabe R, Hasegawa K, Kita T, Kimura T: MicroRNA-133 regulate s the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes. Biochem Biophys Res Commun 2009;389:315-320.
42. Belevych AE, Sansom SE, Terentyeva R, Ho HT, Nishijima Y, Martin MM, Jindal HK, Rochira JA, Kunitomo Y, Abdellatif M, Carnes CA, Elton TS, Gyorke S,Terentyev D. MicroRNA-1 and-133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 com plex. PLoS One 2011;6:e28324.